SOLIQUA 100/33 patients start with a dose of 15 Units*
SOLOSTAR TECHNOLOGY YOU AND YOUR OFFICE STAFF WILL FIND FAMILIAR
Limitations of Use:
Contraindications
Warnings and Precautions
Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Changes should be made cautiously and the frequency of blood glucose monitoring should be increased. Adjustments in concomitant oral antidiabetic treatment may be needed.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.
Most Common Adverse Reactions
The most common adverse reactions reported in ≥5% of patients treated with SOLIQUA 100/33 include hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, and headache.
Drug Interactions
References:
References:
1. SOLIQUA 100/33 Prescribing Information.
2. Data on file. CSR 12404. Sanofi US.
OAD, oral antidiabetic therapy.
References:
1. Data on file. CSR 12404. Sanofi US.
2. SOLIQUA 100/33 Prescribing Information.
OAD, oral antidiabetic therapy.
References:
Reference:
1. SOLIQUA 100/33 Prescribing Information.
Reference:
1. SOLIQUA 100/33 Prescribing Information.
Reference:
1. SOLIQUA 100/33 Prescribing Information.
OAD, oral antidiabetic therapy.